SCHEMBL690576

SCHEMBL690576

COc1ccc2c(c1)[nH]c1c(C)c(OCc3ccccc3)ccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.59
DYRK1A Q13627 8/20 0.51
ACHE P22303 2/20 0.51
KDM4E B2RXH2 1/20 0.51
DYRK3 O43781 1/20 0.51
CCNT1 O60563 1/20 0.51
CCNB2 O95067 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CDK1 P06493 1/20 0.51
CYP3A4 P08684 1/20 0.51
ADRA2A P08913 1/20 0.51
CYP2D6 P10635 1/20 0.51
CCNB1 P14635 1/20 0.51
HPGD P15428 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
CCNA2 P20248 1/20 0.51
SLC6A2 P23975 1/20 0.51
CDK2 P24941 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18487311 0.88 MAOB (0.52) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL18487330 0.86 MAOA (0.57) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL16450986 0.84 MAOA (0.55) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL18487325 0.84 DYRK1A (0.49) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL7256169 0.82 CTSV (0.66) MAOAKDM4EALDH1A1CYP3A4CYP2D6
SCHEMBL690131 0.81 KDM4E (0.53) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL12646132 0.81 DYRK1A (0.54) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL18487755 0.81 L3MBTL1 (0.49) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL18487754 0.81 DYRK1A (0.46) MAOADYRK1AACHEKDM4EDYRK3
SCHEMBL30939879 0.78 MAOA (0.61) MAOADYRK1AACHEKDM4EDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10457639-B2 Fluorescent regulators of RASSF1A expression and human cancer cell proliferation GEORGETOWN UNIVERSITY (US) 2019-10-29 US disclosed
US-10266490-B2 Radioprotector compounds GEORGETOWN UNIVERSITY (US) 2019-04-23 US disclosed
US-20150044293-A1 RADIOPROTECTOR COMPOUNDS GEORGETOWN UNIVERSITY (US) 2015-02-12 US disclosed
EP-2484666-A1 Fluorescent regulators of RASSF1A expression and human cancer cell proliferation Georgetown University (US) 2012-08-08 EP disclosed
EP-2323982-B1 FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION UNIV GEORGETOWN (US) 2012-02-29 EP disclosed
US-20110152339-A1 FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION GEORGETOWN UNIVERSITY 2011-06-23 US disclosed
US-20100130579-A1 CANCER THERAPY GEORGETOWN UNIVERSITY (US) 2010-05-27 US disclosed
US-20100130579-A1 CANCER THERAPY GEORGETOWN UNIVERSITY (US) 2010-05-27 US disclosed
WO-2008051523-A2 CARBAZOLE DERIVATIVES USEFUL AS MEDICAMENTS IN CANCER THERAPY GEORGETOWN UNIVERSITY (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152339-A1 FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION RASSF5, RASSF2, MKI67 MAOA 4293/4885DYRK1A 2619/4885ACHE 4748/4885
US-10266490-B2 Radioprotector compounds DDB1, CASP3, BAD MAOA 4560/4885DYRK1A 2038/4885ACHE 4295/4885
US-20100130579-A1 CANCER THERAPY RASSF5, RASSF2, DNMT1 MAOA 4439/4885DYRK1A 4535/4885ACHE 4750/4885
US-20150044293-A1 RADIOPROTECTOR COMPOUNDS DDB1, CASP3, BAD MAOA 4560/4885DYRK1A 2038/4885ACHE 4295/4885
US-10457639-B2 Fluorescent regulators of RASSF1A expression and human cancer cell proliferation RASSF5, RASSF2, MKI67 MAOA 4293/4885DYRK1A 2619/4885ACHE 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.